Compugen's Shares Jump as AstraZeneca Pays $65M Upfront for Rilvegostomig Royalties

Compugen Ltd. (NASDAQ:CGEN) saw its stock shoot up nearly 13% in early trading following a significant deal with AstraZeneca (NASDAQ:AZN).

They locked in a non-dilutive agreement that hands Compugen $65 million upfront by monetizing part of their future royalties from rilvegostomig, a cancer drug that's still navigating clinical phases. There's also a provision for an extra $25 million as a milestone bonus, sweetening the pot further down the line.

This deal doesn't mean Compugen is cashing out entirely-they'll keep most of their royalties and can still earn tiered payments reaching into the mid-single digits on sales. Additional regulatory and commercial milestones could add up to $195 million, letting them ride the upside without giving away the farm.

Rilvegostomig isn't your run-of-the-mill therapy; it's a first-in-class bispecific antibody targeting immune checkpoints PD-1 and TIGIT simultaneously on the same effector cell, something AstraZeneca is testing in 11 ongoing Phase 3 trials across lung, gastrointestinal, and endometrial cancers.

Compugen's CEO, Eran Ophir, emphasized how this deal validates their unique approach to TIGIT inhibition through rilvegostomig's differentiated Fc-reduced design. They're projecting this cash influx will keep their operations funded through 2029, assuming no other major cash events.

The TIGIT-targeting component in rilvegostomig stems from Compugen's wholly-owned COM902 antibody, one of only two Fc-reduced anti-TIGIT monoclonal antibodies in clinical development, marking it as a rare player in a promising immunotherapy niche.

This move could well give Compugen a stronger runway and AstraZeneca a pivotal wound in the cancer treatment arsenal. How the ongoing Phase 3 trials pan out will be a big deal for both, but for now, the market clearly took the news as a positive catalyst.

Not every day a mid-stage immunotherapy company snaps up a $65 million upfront payment while keeping significant royalty rights intact. That balance of immediate cash and future upside is a neat trick, especially in the high-stakes oncology field.

Meanwhile, AstraZeneca's slight dip reflects a minor market blip rather than any loss of confidence in their drug pipeline, which continues to power through these critical trials.